Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association
|
April 24, 2024
Increased Virtual Visits to Physicians During the COVID-19 Pandemic and Estimated Impact on Physician Compensation: The Case of Lung and Colorectal Cancers, Chronic Obstructive Pulmonary Diseases, and Heart Failure in Alberta, Canada
Nguyen Xuan Thanh, Arianna Waye, Douglas Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
Reovirus as a viable therapeutic option for the treatment of multiple myeloma
Chandini M Thirukkumaran, Zhong Qiao Shi, Joanne Luider, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 31, 2012
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities
Andrew Daly, Mary L Savoie, Michelle Geddes, et al.
Ejhaem
|
January 27, 2025
Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial
Arjun Pandey, Kim Roos, Yidi Jiang, et al.
Clinical Transplantation
|
May 24, 2022
Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant
Alex Chi Fung Kwan, Nikki Blosser, Sunita Ghosh, et al.
Blood Advances
|
January 4, 2018
Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination
Kareem Jamani, Judy MacDonald, Martin Lavoie, et al.
European Journal of Haematology
|
May 9, 2023
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL
Irina Amitai, Kim Roos, Iran Rashedi, et al.
Leukemia & Lymphoma
|
September 27, 2024
Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma
Sila Usta, Alexandra Misura, Iran Rashedi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 25, 2008
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
Michelle Geddes, S Bill Kangarloo, Farrukh Naveed, et al.
Cell Reports
|
September 23, 2016
Human iNKT Cells Promote Protective Inflammation by Inducing Oscillating Purinergic Signaling in Monocyte-Derived DCs
Xuequn Xu, Ginger M Pocock, Akshat Sharma, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association
|
April 24, 2024
Increased Virtual Visits to Physicians During the COVID-19 Pandemic and Estimated Impact on Physician Compensation: The Case of Lung and Colorectal Cancers, Chronic Obstructive Pulmonary Diseases, and Heart Failure in Alberta, Canada
Nguyen Xuan Thanh, Arianna Waye, Douglas Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
Reovirus as a viable therapeutic option for the treatment of multiple myeloma
Chandini M Thirukkumaran, Zhong Qiao Shi, Joanne Luider, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 31, 2012
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities
Andrew Daly, Mary L Savoie, Michelle Geddes, et al.
Ejhaem
|
January 27, 2025
Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial
Arjun Pandey, Kim Roos, Yidi Jiang, et al.
Clinical Transplantation
|
May 24, 2022
Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant
Alex Chi Fung Kwan, Nikki Blosser, Sunita Ghosh, et al.
Blood Advances
|
January 4, 2018
Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination
Kareem Jamani, Judy MacDonald, Martin Lavoie, et al.
European Journal of Haematology
|
May 9, 2023
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL
Irina Amitai, Kim Roos, Iran Rashedi, et al.
Leukemia & Lymphoma
|
September 27, 2024
Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma
Sila Usta, Alexandra Misura, Iran Rashedi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 25, 2008
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
Michelle Geddes, S Bill Kangarloo, Farrukh Naveed, et al.
Cell Reports
|
September 23, 2016
Human iNKT Cells Promote Protective Inflammation by Inducing Oscillating Purinergic Signaling in Monocyte-Derived DCs
Xuequn Xu, Ginger M Pocock, Akshat Sharma, et al.
Page
of 8